SAN DIEGO & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Synteract, a full-service, international contract research organization (CRO), is announcing that Mary Mattes has joined as senior vice president, Biometrics and Drug Safety. Mattes joins from senior level roles in biometrics and data management at Accelovance and PRA. At Synteract, she will define, develop, and ensure quality delivery of data management, biostatistics, medical writing, and safety services globally across Phase I-IV trials for clients and help select and implement technology enhancements to continue to advance the company.
“Mary brings extensive CRO leadership to our organization from a distinguished career focused on building teams and processes that seamlessly integrate operational and technology aspects to support complex, global clinical trials,” said Steve Powell, CEO of Synteract. “Mary and I have worked together previously, and, therefore, I am confident she will be a valuable addition to our team and for our clients. It is my pleasure to welcome her to Synteract.”
Mattes draws on 20 years of experience in the clinical trial research industry, managing project management and biometrics departments with 20 to 500 professionals worldwide at multi-national CROs. Most recently she was executive vice president, Global Biometrics & Information Technology at Accelovance, where she was promoted from vice president, Data Management and Biostatistics. Prior to that she spent ten years at PRA, where she held increasingly more senior level roles in data management and analysis and was most recently executive director, Clinical Informatics Delivery. In this position, she was head of the department responsible for client relationships and delivery of Phase I-IV drug development services across biometrics and drug safety.
Mattes holds a bachelor’s degree in biology, with a minor in chemistry, from The College of Saint Rose.
About Synteract
With 800 staff members across 21 countries, Synteract is an international full-service contract research organization supporting biopharmaceutical companies in all phases of clinical development. Synteract has conducted Phase I-IV studies on six continents and in more than 60 countries, offering a notable depth of expertise in oncology, CNS, and ophthalmology, indications, as well as rare and orphan, pediatric, and immunotherapy studies. With its “Shared Work – Shared Vision” philosophy, Synteract provides customized services collaboratively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.
